News
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced yesterday.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced yesterday.